Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 601–700 of 1,019
Nanomedicine for Gene Delivery for the Treatment of Cardiovascular Diseases
Yan, C., Quan, X., & Feng, Y. (2018) · Current Gene Therapy · doi:10.2174/1566523218666181003125308 · Cited by 38
PCSK9 Inhibition to Reduce Cardiovascular Events
Dullaart, R. P. F. (2017) · New England Journal of Medicine · doi:10.1056/nejme1703138 · Cited by 37
Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia
Rosenson, R. S., Jacobson, T. A., Preiss, D., Djedjos, C. S., Dent, R., Bridges, I., & Miller, M. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6666-1 · Cited by 36
“Full details of the exclusion criteria have been published elsewhere [16].”
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
Chen, Z., Shao, W., Li, Y., Zhang, X., Geng, Y., Ma, X., Tao, B., Ma, Y., Yi, C., Zhang, B., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2023.155774 · Cited by 36
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 36
New Insights Into the Treatment of Hyperlipidemia: Pharmacological Updates and Emerging Treatments
Abbasi, S., Khan, A. A., & Choudhry, M. W. (2024) · Cureus · doi:10.7759/cureus.63078 · Cited by 49
The functions of apolipoproteins and lipoproteins in health and disease
Ma, Z., Zhong, J., Tu, W., Li, S., & Chen, J. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00218-7 · Cited by 41
Reality of a Vaccine in the Prevention and Treatment of Atherosclerosis
García‐González, V., Delgado‐Coello, B., Pérez‐Torres, A., & Mas‐Oliva, J. (2015) · Archives of Medical Research · doi:10.1016/j.arcmed.2015.06.004 · Cited by 36
Navarese, E. P., Kołodziejczak, M. M., Dimitroulis, D., Wolff, G., Busch, H. L., Devito, F., Sionís, A., & Ciccone, M. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv045 · Cited by 38
Kunutsor, S. K., Khan, H., Nyyssönen, K., & Laukkanen, J. A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.069 · Cited by 36
“Evidently, interventions such as nutritional and lifestyle modification have not shown any benefits in decreasing levels of Lp(a); (ii) in addition, given that interventions that specifically lower Lp(a) levels are currently not available, it has been difficult to perform intervention trials to establish the clinical…”
BackgroundFala, L. (2016) · Europe PMC (PubMed Central) · Cited by 36
New directions for pharmacotherapy in the treatment of acute coronary syndrome
Adamski, P., Adamska, U., Ostrowska, M., Koziński, M., & Kubica, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241234 · Cited by 37
Hu, D., Yang, Y., & Peng, D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.064 · Cited by 39
Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)
Shahawy, M. E., Cannon, C. P., Blom, D. J., McKenney, J. M., Cariou, B., Lecorps, G., Pordy, R. C., Chaudhari, U., & Colhoun, H. M. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.06.023 · Cited by 37
Self-citationToth, P. P., Jones, S. R., Monsalvo, M. L., Elliott‐Davey, M., López, J. A. G., & Banach, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014129 · Cited by 37
Cordero, A., Olmo, M. R. F., Quiroga, G. A. C., Romero‐Menor, C., Fácila, L., Seijas‐Amigo, J., Fornovi, A., Murillo, J. R., Rodríguez‐Mañero, M., Mora, M. C. B., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001205 · Cited by 36
“Cordero reports (1) honoraria for lectures from AstraZeneca, BristolMyers Squibb, Boehringer Ingelheim, Ferrer, Mylan, Sanofi, and Amgen and (2) consulting fees from AstraZeneca, Sanofi, Ferrer, and Amgen.”
Background2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
(2020) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2020.05.011 · Cited by 36
Ji, C., Bai, J., Zhou, J., Zou, Y., & Yu, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15460 · Cited by 37
“The results were mostly consistent with large landmark randomized controlled trials (RCTs), such as ODYSSEY LONG TERM and OSLER-1, which found that the PCSK9 inhibitors exhibit higher rates of ISRs and muscle-related AEs than the placebo.(19,20) Furthermore, several frequently reported AEs listed on the drug label sho…”
MethodResultZhang, X., Geng, T., Li, N., Wu, L., Wang, Y., Zheng, D., Guo, B., & Wang, B. (2022) · Nutrients · doi:10.3390/nu15010069 · Cited by 37
Recent advances in the pharmacological management of hypercholesterolaemia
Ajufo, E., & Rader, D. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00074-7 · Cited by 42
Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies)
Teramoto, T., Kobayashi, M., Uno, K., Takagi, Y., Matsuoka, O., Sugimoto, M., Inoue, S., Minami, F., & Baccara‐Dinet, M. T. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.04.011 · Cited by 38
Gencer, B., Koskinas, K. C., Räber, L., Karagiannis, A., Nanchen, D., Auer, R., Carballo, D., Carballo, S., Klingenberg, R., Heg, D., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006537 · Cited by 35
PCSK9 and the nervous system: a no-brainer?
Jaafar, A. K., Techer, R., Chemello, K., Lambert, G., & Bourane, S. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100426 · Cited by 42
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 36
Poirier, S., Hamouda, H. A., Villeneuve, L. R., Demers, A., & Mayer, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157230 · Cited by 41
PCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 38
A Genetic Approach to the Association Between PCSK9 and Sepsis
Feng, Q., Wei, W., Chaugai, S., Leon, B. G. C., Kawai, V. K., Leon, D. A. C., Jiang, L., Zhong, X. Y., Liu, G., Ihegword, A., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11130 · Cited by 36
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 39
“SEY LONG-TERM and ODYSSEY JAPAN phase 3 studies [74,75].”
BackgroundDyslipidemia and prevention of atherosclerotic cardiovascular disease in the elderly
LUCCHI, T. (2022) · Minerva Medica · doi:10.23736/s0026-4806.21.07347-x · Cited by 41
Technological readiness and implementation of genomic‐driven precision medicine for complex diseases
Franks, P. W., Melén, E., Friedman, M., Sundström, J., Kockum, I. S., Klareskog, L., Almqvist, C., Bergen, S. E., Czene, K., Hägg, S., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13330 · Cited by 53
Korneva, V., Kuznetsova, T. Y., & Julius, U. (2021) · Biomedicines · doi:10.3390/biomedicines9091271 · Cited by 39
“PCSK9i lower Lp(a) concentrations by approximately 25% [13,14] and it was observed, that it can reduce [15–17].”
BackgroundLong-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 38
“Some studies have reported a slight increased rate of adverse neurocognitive events within the PCSK9-targeted therapy group when compared with the placebo or other treatments, raising some concerns regarding the long-term neurological safety of PCSK9-targeted therapy [18, 82, 83].”
BackgroundResultSelf-citationRamanathan, A. A., Gusarova, V., Stahl, N., Gurnett-Bander, A., & Kyratsous, C. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154498 · Cited by 35
The Application of Genomics in Diabetes: Barriers to Discovery and Implementation
Floyd, J. S., & Psaty, B. M. (2016) · Diabetes Care · doi:10.2337/dc16-0738 · Cited by 39
Management of cardiovascular risk factors in patients with ANCA‐associated vasculitis
Bramlage, C. P., Kröplin, J., Wallbach, M., Minguet, J., Smith, K. H., Lüders, S., Schrader, J., Patschan, S., Groß, O., Deutsch, C., et al. (2017) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12709 · Cited by 35
“A further option in the future may the pharmacological treatment with proprotein convertase subtilisin/kexin type 9 inhibitors such as alirocumab and evolocumab, which have been shown to reduce LP(a) levels by approximately 25% to 30%.(41,42) The relative contribution that high LP(a) levels make to CV risk in patients…”
BackgroundBaragetti, A., Grejtáková, D., Casula, M., Olmastroni, E., Jotti, G. S., Norata, G. D., Catapano, A. L., & Bellosta, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.025 · Cited by 36
Mu, G., Xiang, Q., Zhou, S., Liu, Z., Qi, L., Jiang, J., Gong, Y., Xie, Q., Wang, Z., Zhang, H., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01259-4 · Cited by 39
Susan-Resiga, D., Girard, E., Kiss, R. S., Essalmani, R., Hamelin, J., Asselin, M.-C., Awan, Z., Butkinaree, C., Fleury, A., Soldera, A., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.769430 · Cited by 35
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
Leiter, L. A., Müller‐Wieland, D., Baccara‐Dinet, M. T., Letierce, A., Samuel, R., & Cariou, B. (2017) · Diabetic Medicine · doi:10.1111/dme.13450 · Cited by 34
Roth, E. M., Bujas‐Bobanovic, M., Louie, M. J., & Cariou, B. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.008 · Cited by 34
Atherosclerosis: Recent trials, new targets and future directions
Ladeiras‐Lopes, R., Agewall, S., Tawakol, A. A., Staels, B., Stein, E. A., Mentz, R. J., Leite-Moreira, A. F., Zannad, F. M., & Köenig, W. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.013 · Cited by 38
Walsh, M. T., & Hussain, M. M. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2016.1221883 · Cited by 36
Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options
Anagnostis, P. G., Karras, S. Ν., Lambrinoudaki, I. V., Stevenson, J. C., & Goulis, D. G. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12903 · Cited by 36
Eisenga, M. F., Zelle, D. M., Sloan, J. H., Gaillard, S., Bakker, S. J. L., & Dullaart, R. P. F. (2017) · Diabetes Care · doi:10.2337/dc16-2258 · Cited by 35
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia
Shrestha, P., van de Sluis, B., Dullaart, R. P. F., & van den Born, J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.12.001 · Cited by 35
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation
Kühl, M., Binner, C., Jozwiak, J., Fischer, J., Hahn, J., Addas, A., Dinov, B., Garbade, J., Hindricks, G., & Borger, M. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210373 · Cited by 36
PCSK9: A Potential Therapeutic Target for Sepsis
Yuan, Y., Wu, W., Sun, S., Zhang, Y., & Chen, Z. (2020) · Journal of Immunology Research · doi:10.1155/2020/2687692 · Cited by 35
Jiang, Q., Qin, D., Yang, L., Lin, Y., Zhai, L., Zhang, Y., Yang, G., Wang, K., Tong, D., Li, X., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.011 · Cited by 39
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Jia, X., Rifai, M. A., Saeed, A., Ballantyne, C. M., & Virani, S. S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s275739 · Cited by 35
“Some earlier trials of evolocumab and alirocumab reported a low but significant increase in neurocognitive side effects with PCSK9 inhibitors leading to some concerns for reducing LDL-C to ultra-low levels.(14,15,61) However, results from the large FOURIER and ODYSSEY-OUTCOMES trials did not show a significant increas…”
BackgroundResultSchremmer, J., Busch, L., Baasen, S., Heinen, Y., Sansone, R., Heiß, C., Kelm, M., & Stern, M. E. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104513 · Cited by 37
Jones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 34
Low High-Density Lipoprotein and Risk of Myocardial Infarction
Ramirez, A., & Hu, P. P. (2015) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s26624 · Cited by 37
CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia
Chadwick, A. C., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309326 · Cited by 34
PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol
Wang, Y., & Liu, Z. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666180423111442 · Cited by 38
Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism
Ellis, K. L., Hooper, A. J., Burnett, J. R., & Watts, G. F. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.69 · Cited by 34
Non-ST Elevation Acute Coronary Syndromes: A Comprehensive Review
Bob‐Manuel, T., Ifedili, I., Reed, G. L., Ibebuogu, U. N., & Khouzam, R. N. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.04.006 · Cited by 38
PCSK9 and infection: A potentially useful or dangerous association?
Khademi, F., Momtazi‐Borojeni, A. A., Reiner, Ž., Banach, M., Al‐Rasadi, K., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26040 · Cited by 33
“These agents have been shown inmany trials, aswell as in pooled andmeta-analyses, to efficiently reduce plasma LDL-C by around 60%, and reduce cardiovascular events by significant rates ranging from 15% to 50% (Robinson et al., 2015; Sabatine et al., 2015, 2017a).”
BackgroundFrom lipid locus to drug target through human genomics
van der Laan, S. W., Harshfield, E. L., Hemerich, D., Stacey, D., Wood, A., & Asselbergs, F. W. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy120 · Cited by 38
Taskinen, M., Prato, S. D., Bujas‐Bobanovic, M., Louie, M. J., Letierce, A., Thompson, D. E., & Colhoun, H. M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.017 · Cited by 34
Health and societal implications of medical and technological advances
Dzau, V. J., & Balatbat, C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau4778 · Cited by 33
Mahmood, T. A., Minnier, J., Ito, M. K., Li, Q. H., Koren, A., Kam, I. W., Fazio, S., & Shapiro, M. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320915803 · Cited by 33
Cordero, A., Rodríguez‐Mañero, M., Fácila, L., Fernández-Olmo, M. R., Gómez-Martínez, M. J., Valle, A., Castellano, J. M., Toro, M. M., Seijas‐Amigo, J., Vicedo-López, Á., et al. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00557-6 · Cited by 33
Manejo do risco cardiovascular: dislipidemia
Izar, M. C. D. O., Fonseca, F. A. H., Faludi, A. Á., de Araújo, D. B., Valente, F., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-19 · Cited by 33
Skeby, C. K., Hummelgaard, S., Gustafsen, C., Petrillo, F., Frederiksen, K. P., Olsen, D., Kristensen, T., Ivarsen, P., Madsen, P., Christensen, E., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.06.024 · Cited by 35
Association between the DOCK7, PCSK9 and GALNT2 Gene Polymorphisms and Serum Lipid levels
Guo, T., Yin, R., Huang, F., Yao, L., Lin, W., & Pan, S. (2016) · Scientific Reports · doi:10.1038/srep19079 · Cited by 34
Relation between plasma and brain lipids
Wellington, C. L., & Frikke-Schmidt, R. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000291 · Cited by 33
PCSK 9 in diabetic kidney disease
Elewa, U., Fernández‐Fernández, B., Mahíllo, I., Martín-Cleary, C., Sanz, A. B., Sánchez-Niño, M. D., & Ortíz, A. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12661 · Cited by 38
Remembering Statins: Do Statins Have Adverse Cognitive Effects?
Bitzur, R. (2016) · Diabetes Care · doi:10.2337/dcs15-3022 · Cited by 33
Rubba, P., Gentile, M., Marotta, G., Iannuzzi, A., Sodano, M., Simone, B. D., Jossa, F., Iannuzzo, G., Giacobbe, C., Taranto, M. D. D., et al. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317702040 · Cited by 33
Martinez, J.-M., Brunet, A., Hurbin, F., DiCioccio, A. T., Rauch, C., & Fabre, D. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0669-y · Cited by 33
“Data were derived from phase I (NCT01026597, NCT01074372, NCT01161082 [19], NCT01448317, and NCT01723735), phase II (NCT01288443, NCT01288469 [20, 21], NCT01812707, and NCT01576484), and phase III (NCT01644188 [ODYSSEY COMBO II] [10], NCT01644474 [ODYSSEY MONO] [8], NCT01623115 [ODYSSEY FH I] [9], and NCT01507831 [ODY…”
Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia
Sun, Y., Lv, Q., Guo, Y., Wang, Z., Huang, R., Gao, X., Han, Y., Yao, Z., Zheng, M., Luo, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.012 · Cited by 32
Imaging Atherosclerotic Plaque Calcification: Translating Biology
Bailey, G., Meadows, J. L., & Morrison, A. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0601-6 · Cited by 37
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Oktay, A. A., Aktürk, H. K., Esenboğa, K., Javed, F., Polin, N. M., & Jahangir, E. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.05.001 · Cited by 36
“Alirocumab and evolocumab (PCSK9 inhibitors in the market) can result in up to 60% reduction in LDL-C levels on top of a baseline statin therapy.(163,164) A meta-analysis of three RCTs demonstrated that, compared to placebo, evolocumab therapy in patients with T2DM reduces LDL-C >60%, similar to the reduction in patie…”
BackgroundStam‐Slob, M. C., van der Graaf, Y., de Boer, A., Greving, J. P., & Visseren, F. L. J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.080 · Cited by 37
Cannon, C. P., de Lemos, J. A., Rosenson, R. S., Ballantyne, C. M., Liu, Y., Yazdi, D., Elliott‐Davey, M., Mues, K. E., Bhatt, D. L., & Kosiborod, M. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.10.014 · Cited by 32
Fang, H., Chen, L., & Knight, J. C. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30134-1 · Cited by 32
Treatment of dyslipidemia in kidney transplantation
Ponticelli, C. E., Arnaboldi, L., Moroni, G. L., & Corsini, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1732921 · Cited by 34
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 33
Ying, H., Wang, J., Shen, Z., Wang, M., & Zhou, B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07045-2 · Cited by 35
Taskinen, M.-R., Björnson, E., Kahri, J., Söderlund, S., Matikainen, N., Porthan, K., Ainola, M., Hakkarainen, A., Lundbom, N., Fermanelli, V., et al. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315446 · Cited by 30
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 35
Anti-inflammatory Strategies in Atherosclerosis
Bugger, H., & Zirlik, A. (2021) · Hämostaseologie · doi:10.1055/a-1661-0020 · Cited by 34
Achimastos, A. D., Alexandrides, T., Alexopoulos, D. K., Athyros, V. G., Bargiota, Α., Bilianou, E., Chrysochoou, C., Drogari, E., Elisaf, M., Ganotakis, E., et al. (2016) · HORMONES · doi:10.1007/bf03401398 · Cited by 35
Cardiovascular pharmacogenomics: current status and future directions
Roden, D. M. (2015) · Journal of Human Genetics · doi:10.1038/jhg.2015.78 · Cited by 36
Circulating PCSK9 and Risk of Myocardial Infarction
Laugsand, L. E., Åsvold, B. O., VATTEN, L. J., Janszky, I., Platou, C., Michelsen, A. E., Damås, J. K., Aukrust, P., & Ueland, T. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.06.007 · Cited by 33
“The effect of the medication is currently under investigation in other high-risk populations (1,3,4).”
BackgroundLee, J. S., O’Connell, E. M., Pacher, P., & Lohoff, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081758 · Cited by 31
New Approaches for Targeting PCSK9: Small-Interfering Ribonucleic Acid and Genome Editing
Oostveen, R. F., Khera, A. V., Kathiresan, S., Stroes, E. S. G., Fitzgerald, K., Harms, M. J., Oakes, B. L., & Kastelein, J. J. P. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.122.317963 · Cited by 31
Self-citationA promising therapy for fatty liver disease: PCSK9 inhibitors
Han, L., Wu, L., Yin, Q., Li, L., Zheng, X., Du, S., Huang, X., Bai, L., Wang, Y., & Bian, Y. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155505 · Cited by 31
Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed Hyperlipemia
Xu, M., Wang, Z., Zhang, Y., Liu, Y., Huang, R., Han, X., Yao, Z., Sun, J., Tian, F., Hu, X., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.035 · Cited by 31
Yang, J., Wang, Y., Zhou, T., Wong, L.-Y., Tian, X.-Y., Hong, X., Lai, W., Au, K., Wei, R., Liu, Y., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.027 · Cited by 31
Shin, J., Chung, J., Jang, H.-S., Lee, J., Hong, K., Bang, O. Y., Kim, G., & Seo, W. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319830503 · Cited by 33
Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects
Mijares, A. H., Ascaso, J. F., Blasco, M., Brea, Á., Díaz, Á., Mantilla, T., Pedro‐Botet, J., Pintó, X., & Millán, J. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.02.002 · Cited by 37
Risk Factors for Ischemic Heart Disease
Bisciglia, A., Pasceri, V., Irini, D., Varveri, A., & Speciale, G. (2019) · Reviews on Recent Clinical Trials · doi:10.2174/1574887114666190328125153 · Cited by 40
Ortega-Rivera, O. A., Pokorski, J. K., & Steinmetz, N. F. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100014 · Cited by 31
Zheutlin, A. R., Derington, C. G., Herrick, J. S., Rosenson, R. S., Poudel, B., Safford, M. M., Brown, T. M., Jackson, E. A., Woodward, M., Reading, S. R., et al. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008861 · Cited by 36
Galve, E., Cordero, A., Cequier, A. R., Ruiz, E., & González‐Juanatey, J. R. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.02.012 · Cited by 36
Danese, M. D., Gleeson, M. L., Kutikova, L., Griffiths, R. I., Khunti, K., Seshasai, S. R. K., & Ray, K. K. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013851 · Cited by 31
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 32
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.